Increased pretransplant QT dispersion as a risk factor for the development of cardiac complications during and after preparative conditioning for pediatric allogeneic hematopoietic stem cell transplantation

Pediatric Transplantation

Volumn 14, Issue 8, 2010, Pages 986-992

  Motoki, Noriko ^a   Shimizu, Takashi ^a   Akazawa, Yohei ^a   Saito, Shoji ^a   Tanaka, Miyuki ^a   Yanagisawa, Ryu ^a   Motoki, Hirohiko ^a   Nakazawa, Yozo ^b   Sakashita, Kazuo ^a   Iwasaki, Yasushi ^c   Shiohara, Masaaki ^a   Koike, Kenichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b National Nagano Hospital   (Japan)

^c Matsumoto Hospital   (Japan)

Author keywords

arrhythmia; cardiotoxicity; heart failure; hematopoietic stem cell transplantation; QT dispersion

Indexed keywords

CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIURETIC AGENT; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; IDARUBICIN; MITOXANTRONE; PIRARUBICIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CARDIOMEGALY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; ECHOCARDIOGRAPHY; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; MALE; PRESCHOOL CHILD; QT DISPERSION; SCHOOL CHILD; WHOLE BODY RADIATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ARRHYTHMIAS, CARDIAC; CHILD; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS; STATISTICS, NONPARAMETRIC; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 78649848061     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2010.01389.x     Document Type: Article

References (48)

1. Pui CH, Campana D, Evans WE,. Childhood acute lymphoblastic leukemia: Current status and future perspectives. Lancet Oncol 2001: 2: 597-607.
2. Pui CH, Evans WE,. Acute lymphoblastic leukemia. N Engl J Med 1998: 339: 605-615.
3. Tomizawa D, Tabuchi K, Kinoshita A, et al. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: Long-term outcome of the children with AML treated on two consecutive trials of Tokyo children's cancer study group. Pediatr Blood Cancer 2007: 49: 127-132.
4. Grimm W, Steder U, Menz V, Hoffmann J, Grote F, Maisch B,. Clinical significance of increased OT dispersion in the 12-lead standard ECG for arrhythmia risk prediction in dilated cardiomyopathy. Pacing Clin Electrophysiol 1996: 19: 1886-1889.
5. Dritsas A, Sbarouni E, Gilligan D, Nihoyannopoulos P, Oalley CM,. QT-interval abnormalities in hypertrophic cardiomyopathy. Clin Cardiol 1992: 15: 739-742.
6. Barr CS, Naas AA, Fenwick M, Struthers A,. Enalapril reduces QTc dispersion in mild congestion heart failure secondary to coronary artery disease. Am J Cardiol 1997: 79: 328-333.
7. Sarubbi B, Orditura M, Ducceschi V, et al. Ventricular repolarization time indexes following anthracycline treatment. Heart Vessels 1997: 12: 262-266.
8. Nousiainen T, Vanninen E, Rantala A, Jantunen E, Hartikainen J,. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. J Intern Med 1999: 245: 359-364.
9. Orditura M, Sarubbi B, Devita F, et al. Prolonged corrected QT dispersion: Early sign of doxorubicin cardiotoxicity? Oncol Rep 1997: 4: 1047-1050.
10. Gulen H, Kazanci E, Mese T, et al. Cardiac functions by myocardial performance index and QT dispersion in survivors of childhood lymphoblastic leukemia. Minerva Pediatr 2007: 59: 107-113.
11. Gupta M, Thaler HT, Friedman D, Steinherz L,. Presence of prolonged dispersion of QT intervals in late survivors of childhood. Pediatr Hematol Oncol 2002: 19: 533-542.
12. Nakamae H, Hino M, Akahori M, et al. Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation. Am J Hematol 2004: 76: 1-7.
13. Yan GX, Antzelevitch C,. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 1998: 98: 1928-1936.
14. Kapanou EA, Vyssoulis GP, Psichoigios A, et al. Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Am Heart J 1998: 136: 765-768.
15. Bazett HC,. An analysis of the time-relations of electrocardiograms. Heart 1920: 7: 353-370.
16. Macfarlane PW, Mclaughlin SC, Rodger JC,. Influence of lead selection of population on automated measurement of QT dispersion. Circulation 1998: 98: 2160-2167.
17. Van De Loo A, Arendts W, Hohnloser SH,. Variability of QT dispersion measurements in the surface electrocardiogram in patients with acute myocardial infarction and in normal subjects. Am J Cardiol 1994: 74: 1113-1118.
18. Surawics B,. Will QT dispersion play a role in clinical decision-making? J Cardiovasc Electrophysiol 1996: 7: 777-784.
19. Mckee PA, Castelli WP, Mcnamara PM, Kannel WB,. The natural history of congestive heart failure: The Framingham study. N Engl J Med 1971: 285: 1441-1446.
20. Herait P, Poutignat M, Marty M, Bugat R,. Early assessment of a new anticancer drug analogue-are the historical comparisons obsolete-the French experience with pirarubicin. Eur J Cancer 1992: 28A: 1670-1676.
21. Casazza AM, Bertazzori C, Pratesi G, Bellini O, Marco A,. Antileukemic activity and cardiac toxicity of 4-demethoxydaunorubicin (4-DMD) in mice. Proc Am Assoc Cancer Res 1979: 20: 16.
22. Dalient L, Rizzoli G, Menti L, et al. Accuracy of electrocardiographic indicesin predicting life threatening ventricular arrhythmias in patients operated for tetralogy of Fallot. Heart 1999: 81: 650-655.
23. Huh J, Noh CI, Yun YS,. The usefulness of surface electrocardiogram as a prognostic predictor in children with idiopathic dilated cardiomyopathy. J Korean Med Sci 2004: 19: 652-655.
24. Yetman AT, Hamilton RM, Benson LN, Mccrindle BW,. Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. JACC 1998: 32: 1943-1950.
25. Das BB, Sharma J,. Repolarization abnormalities in children with a structurally normal heart and ventricular Ectopy. Pediatr Cardiol 2004: 25: 354-356.
26. Malik M, Batchvarov NB,. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol 2000: 36: 1749-1766.
27. Cazin B, Gorin NC, Laporte JP, et al. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer 1986: 57: 2061-2069.
28. Steinherz LJ, Steinherz PG, Mangiacasale D, et al. Cardiac changes with cyclophosphamide. Med Pediatr Oncol 1981: 9: 417-422.
29. Lehmann S, Isberg B, Ljungmann P, Paul C,. Cardiac systolic function before and after hematopoietic stem cell transplantation. Bone Marrow Transplant 2000: 26: 187-192.
30. Goldberg MA, Antin JH, Guinan EC, Rappeport JM,. Cyclophosphamide cardiotoxicity: An analysis of dosing as a risk factor. Blood 1986: 68: 1114-1118.
31. Brockstein BE, Smiley C, Al-Sadir J, Williams SF,. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: Prognostic factors. Bone Marrow Transplant 2000: 25: 885-894.
32. Bearman SI, Petersen FB, Schor RA, et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: Risk for cardiac toxicity. Bone Marrow Transplant 1990: 5: 173-177.
33. Hertstein B, Stefanic M, Schmeiser T, et al. Cardiac toxicity of bone marrow transplantation: Predictive value of cardiologic evaluation before transplant. Bone Marrow Transplant 1994: 12: 998-1004.
34. Fujimaki K, Maruta A, Yoshida M, et al. Severe cardiac toxicity in hematopoietic stem cell transplantation: Predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 2001: 27: 307-310.
35. Bristow MR, Billingham ME, Mason JW, Daniels JR,. Clinical spectrum of anthracycline cardiotoxicity. Cancer Treat Rep 1978: 12: 873-879.
36. Lefrak EA, Pitha J, Rosenhei S, Gottlieb JA,. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973: 33: 302-314.
37. Schwartz RG, Mckenzie WB, Alexander S, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiography. Am J Med 1987: 82: 1109-1118.
38. Buzdar AU, Marcus C, Smith TL, Blunmenscein GR,. Early and delayed clinical cardiotoxity of doxorubicin. Cancer 1985: 55: 2761-2765.
39. Creuzig U, Diekamp S, Zimmermann M, Reinhardt D,. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer 2007: 48: 651-662.
40. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998: 16: 545-550.
41. Schwartz CL, Hobbie WL, Tuesdell S, Constine LC, Clark EB,. Corrected QT interval prolongation in anthracycline-treated survivors of childfood cancer. J Clin Oncol 1993: 11: 1906-1910.
42. Olson RD, Mushlin PS,. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB J 1990: 4: 3076-3086.
43. Minotti G, Cavaliere AF, Mordente A, Rossi M, Schavallo R, Possati G,. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. J Clin Invest 1995: 4: 1595-1605.
44. Nakamae H, Tsumura K, Hino M, Hayashi T, Tatsumi N,. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. Lancet 2000: 355: 805-806.
45. Lee CK, Harman GS, Hohl RJ, Gingrich RD,. Fetal cyclophosphamide cardiomyopathy: Its clinical course and treatment. Bone Marrow Transplant 1996: 18: 573-577.
46. Dagianti A, Vitarelli A, Conde Y, Penco M, Fedele F,. Assessment of regional left ventricular function during exercise test with pulsed tissue Doppler imaging. Am J Cardiol 2000: 86: 30G-32G.
47. Tei C,. New non-invasive index for combined systolic and diastolic ventricular function. J Cardiol 1995: 26: 135-136.
48. Greco S, Troisi F, Burunetti ND, Di Biase M,. Tei index correlates with tissue Doppler parameters and reflects neurohormonal activation in patients with an abnormal transmitral flow pattern. Echocardiography 2009: 26: 1012-1018.